Modification of cutoff values for HE4, CA125, the risk of malignancy index, and the risk of Malignancy Algorithm for ovarian cancer detection in Jakarta, Indonesia

Asian Pacific Journal of Cancer Prevention

Volumn 15, Issue 5, 2014, Pages 1949-1953

  Winarto, Hariyono ^a   Laihad, Bismarck Joel ^a   Nuranna, Laila ^a  

^a UNIVERSITY OF INDONESIA   (Indonesia)

Author keywords

CA125; Human epidydimis protein 4; Ovarian cancer; RMI; ROMA; Tumor marker cutoff values

Indexed keywords

CA 125 ANTIGEN; MEMBRANE PROTEIN; MUC16 PROTEIN, HUMAN; PROTEIN; TUMOR MARKER; WFDC2 PROTEIN, HUMAN;

ADULT; ALGORITHM; BLOOD; FEMALE; HUMAN; INDONESIA; METABOLISM; OVARY TUMOR; RETROSPECTIVE STUDY; RISK; SENSITIVITY AND SPECIFICITY;

ADULT; ALGORITHMS; CA-125 ANTIGEN; FEMALE; HUMANS; INDONESIA; MEMBRANE PROTEINS; OVARIAN NEOPLASMS; PROTEINS; RETROSPECTIVE STUDIES; RISK; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 84899102090     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2014.15.5.1949     Document Type: Article

References (19)

1. Aziz MF (2009). Gynecological cancer in Indonesia. J Gynecol Oncol. 20, 8-10.
2. Bian J, Li B, Kou X-J, Liu T-Z, Ming L (2013). Clinical significance of combined detection of serum tumor markers in diagnosis of patients with ovarian cancer. Asian Pac J Cancer Prev, 13, 6241-43.
3. Boyle P, Levin B (2008). World Cancer Report. In: WHO, editor. Switzerland: International Agency for Research on Cancer.
4. Chang X, Ye X, Dong L, et al (2011). Human epididymis protein 4 (HE4) as a serum tumor biomarker in patients with ovarian carcinoma. Int J Gynecol Cancer. 21, 852-8.
5. Chan KK, Chen CA, Nam JH, et al (2013). The use of HE4 in the prediction of ovarian cancer in Asian women with a pelvic mass. Gynecol Oncol, 128, 239-44.
6. Havrilesky LJ, Whitehead CM, Rubatt JM, et al (2008). Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence. Gynecol Oncol., 110, 374-82.
7. Hennessy BT, Coleman RL, Markman M(2009). Ovarian cancer. Lancet., 374, 1371-82.
8. Holcomb K, Vucetic Z, Miller MC, Knapp RC (2011). Human epididymis protein 4 offers superior specificity in the differentiation of benign and malignant adnexal masses in premenopausal women. Am J Obstet Gynecol., 205, 1-6.
9. Huhtinen K, Suvitie P, Hiissa J, et al (2009). Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts. Br J Cancer, 100, 1315-9.
10. Lin J-Y, Qin J-B, Li X-Y, Dong P, Yin B-D (2012). Diagnostic value of human epididymis protein 4 compared with mesothelin for ovarian cancer: a systematic review and metaanalysis. Asian Pac J Cancer Prev, 13, 5427-32.
11. Mokhtar N, Thevarajah M, Ma N, M I (2012). Human epididymis protein 4 reference intervals in a multiethnic Asian women population. Asian Pac J Cancer Prev, 13, 6391-5.
12. Moore RG, Brown AK, Miller MC, et al (2008). The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol., 108, 402-8.
13. Moore RG, McMeekin DS, Brown AK, et al (2009). A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol, 112, 40-6.
14. Nolen B, Velikokhatnaya L, Marrangoni A, et al (2010). Serum biomarker panels for the discrimination of benign from malignant cases in patients with an adnexal mass. Gynecol Oncol, 117, 440-5.
15. Pauler DK, Menon U, McIntosh M, et al (2001). Factors influencing serum CA125II levels in healthy postmenopausal women. Cancer Epidemiol Biomarkers Prev., 10, 489-93.
16. Rosen DG, Wang L, Atkinson JN, et al (2005). Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecol Oncol, 99, 267-77.
17. Van Gorp T, Cadron I, Despierre E, et al (2011). HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the Risk of Ovarian Malignancy Algorithm. Br J Cancer., 104, 863-70.
18. Wahidin M, Noviani R, Hermawan S, et al (2012). Populationbased cancer registration in Indonesia. Asian Pac J Cancer Prev, 13, 1709-10.
19. Yavuzcan A, Caglar M, Ozgu E, et al (2013). Should cutoff values of the risk of malignancy index be changed for evaluation of adnexal masses in Asian and Pacific populations?. Asian Pac J Cancer Prev, 13, 5455-9.